Several antiandrogens have been approved for the PCa treatment including first-generation antiandrogens such as bicalutamide, flutamide as well as second-generation non-steroidal AR antagonists like enzalutamide, darolutamide, and apalutamide [15–17]. This evidence concerns the gene AR and posterior cortical atrophy.